Cassandra E. Milmont

3.4k total citations · 1 hit paper
13 papers, 1.8k citations indexed

About

Cassandra E. Milmont is a scholar working on Orthopedics and Sports Medicine, Dermatology and Immunology. According to data from OpenAlex, Cassandra E. Milmont has authored 13 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Orthopedics and Sports Medicine, 5 papers in Dermatology and 5 papers in Immunology. Recurrent topics in Cassandra E. Milmont's work include Bone health and osteoporosis research (6 papers), Psoriasis: Treatment and Pathogenesis (5 papers) and Dermatology and Skin Diseases (5 papers). Cassandra E. Milmont is often cited by papers focused on Bone health and osteoporosis research (6 papers), Psoriasis: Treatment and Pathogenesis (5 papers) and Dermatology and Skin Diseases (5 papers). Cassandra E. Milmont collaborates with scholars based in United States, Canada and Belgium. Cassandra E. Milmont's co-authors include Cesar Libanati, Andreas Grauer, Akimitsu Miyauchi, E. Michael Lewiecki, Felicia Cosman, Serge Ferrari, Daria B. Crittenden, Jonathan D. Adachi, Cristiano A. F. Zerbini and Paul Meisner and has published in prestigious journals such as New England Journal of Medicine, Journal of Bone and Mineral Research and Journal of the American Academy of Dermatology.

In The Last Decade

Cassandra E. Milmont

13 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

2016 1.1k citations Felicia Cosman, Daria B. Crittenden et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cassandra E. Milmont United States	11	1.0k	852	842	330	210	13	1.8k
Kyoungah See United States	16	664 0.6×	380 0.4×	501 0.6×	349 1.1×	305 1.5×	36	1.4k
Annette Schlemmer Denmark	13	463 0.4×	258 0.3×	333 0.4×	246 0.7×	61 0.3×	21	1.5k
D Ethgen Belgium	15	1.5k 1.4×	571 0.7×	1.2k 1.4×	172 0.5×	518 2.5×	32	2.2k
Tien‐Tsai Cheng Taiwan	20	269 0.3×	237 0.3×	188 0.2×	293 0.9×	462 2.2×	78	1.5k
Judy Maddox United States	15	2.4k 2.3×	2.0k 2.4×	1.9k 2.3×	112 0.3×	503 2.4×	19	3.7k
Αθανάσιος Παπαθεοδώρου Greece	22	375 0.4×	460 0.5×	563 0.7×	72 0.2×	296 1.4×	90	1.6k
G Sakellariou Greece	17	199 0.2×	187 0.2×	201 0.2×	83 0.3×	95 0.5×	54	719
Nadia Verbruggen United States	16	828 0.8×	729 0.9×	820 1.0×	33 0.1×	102 0.5×	31	1.4k
Masayuki Iyoda Japan	18	85 0.1×	278 0.3×	135 0.2×	313 0.9×	141 0.7×	69	1.2k
Rajesh Bandekar United States	19	69 0.1×	262 0.3×	405 0.5×	159 0.5×	273 1.3×	48	1.3k

Countries citing papers authored by Cassandra E. Milmont

Since Specialization

Citations

This map shows the geographic impact of Cassandra E. Milmont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cassandra E. Milmont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cassandra E. Milmont more than expected).

Fields of papers citing papers by Cassandra E. Milmont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cassandra E. Milmont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cassandra E. Milmont. The network helps show where Cassandra E. Milmont may publish in the future.

Co-authorship network of co-authors of Cassandra E. Milmont

This figure shows the co-authorship network connecting the top 25 collaborators of Cassandra E. Milmont. A scholar is included among the top collaborators of Cassandra E. Milmont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cassandra E. Milmont. Cassandra E. Milmont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Merrill, Joan T., et al.. (2023). Improving resource utilisation in SLE drug development through innovative trial design. Lupus Science & Medicine. 10(2). e000890–e000890. 2 indexed citations

Cosman, Felicia, David L. Kendler, Bente Langdahl, et al.. (2022). Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporosis International. 33(6). 1243–1256. 57 indexed citations

Takada, Junichi, Rajani Dinavahi, Akimitsu Miyauchi, et al.. (2019). Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. Journal of Bone and Mineral Metabolism. 38(3). 310–315. 23 indexed citations

Geusens, Piet, Mary Oates, Akimitsu Miyauchi, et al.. (2019). The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study. JBMR Plus. 3(10). e10211–e10211. 26 indexed citations

Cosman, Felicia, Daria B. Crittenden, Serge Ferrari, et al.. (2018). Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. Journal of Bone and Mineral Research. 33(8). 1407–1416. 56 indexed citations

Lewiecki, E. Michael, Rajani Dinavahi, Peter R. Ebeling, et al.. (2018). One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. Journal of Bone and Mineral Research. 34(3). 419–428. 132 indexed citations

Cosman, Felicia, Daria B. Crittenden, Serge Ferrari, et al.. (2018). FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. Journal of Bone and Mineral Research. 33(7). 1219–1226. 112 indexed citations

Viswanathan, Hema N., Alex Mutebi, Cassandra E. Milmont, et al.. (2017). Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value in Health. 20(8). 1174–1179. 6 indexed citations

Cosman, Felicia, Daria B. Crittenden, Jonathan D. Adachi, et al.. (2016). Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine. 375(16). 1532–1543. 1131 indexed citations breakdown →

10.

Strober, Bruce, Kim Papp, Mark Lebwohl, et al.. (2016). Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology. 75(1). 77–82.e7. 93 indexed citations

11.

Papp, Kim, Alan Menter, Bruce Strober, et al.. (2014). Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 72(3). 436–439.e1. 36 indexed citations

12.

Papp, Kim, Craig L. Leonardi, Alan Menter, et al.. (2014). Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. Journal of the American Academy of Dermatology. 71(6). 1183–1190.e3. 93 indexed citations

13.

Viswanathan, Hema N., et al.. (2014). Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. Journal of Dermatological Treatment. 26(3). 235–239. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact